1 |
Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, et al. Pulmonary arterial hypertension in France: results from a national registry. Am J Respir Crit Care Med 2006;173:1023-30
DOI
ScienceOn
|
2 |
Gali N, Olschewski H, Oudiz RJ, Torres F, Frost A, Ghofrani HA, et al. Ambrisentan for the treatment of pulmonary arterial hypertension: results of the ambrisentan in pulmonary arterial hypertension, randomized, double-blind, placebo-controlled, multicenter, efficacy (ARIES) study 1 and 2. Circulation 2008;117:3010-9
DOI
ScienceOn
|
3 |
Simonneau G, Rubin LJ, Gali N, Barst RJ, Fleming TR, Frost AE, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149:521-30
DOI
PUBMED
ScienceOn
|
4 |
Jing ZC, Xu XQ, Han ZY, Wu Y, Deng KW, Wang H, et al. Registry and survival study in chinese patients with idiopathic and familial pulmonary arterial hypertension. Chest 2007;132:373-9
DOI
ScienceOn
|
5 |
D’Alonzo GE, Barst RJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Survival in patients with primary pulmonary hypertension: results from a national prospective registry. Ann Intern Med 1991;115:343-9
DOI
PUBMED
ScienceOn
|
6 |
Rich S, Dantzker DR, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, et al. Primary pulmonary hypertension:a national prospective study. Ann Intern Med
1987;107:216-23
DOI
PUBMED
ScienceOn
|
7 |
Thenappan T, Shah SJ, Rich S, Gomberg-Maitland. A USA-based registry for pulmonary arterial hypertension: 1982-2006. Eur Respir J 2007;30:1103-10
DOI
ScienceOn
|
8 |
Peacock AJ, Murphy NF, McMurray JJ, Caballero L, Stewart S. An epidemiological study of pulmonary arterial hypertension. Eur Respir J 2007;30:104-9
DOI
ScienceOn
|
9 |
Rai PR, Cool CD, King JA, Stevens T, Burns N, Winn RA, et al. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178:558-64
DOI
ScienceOn
|
10 |
Sztrymf B, Ya ci A, Girerd B, Humbert M. Genes and
pulmonary arterial hypertension. Respiration 2007;74:123-32
DOI
ScienceOn
|
11 |
Elliott CG, Glissmeyer EW, Havlena GT, Carlquist J, McKinney JT, Rich S, et al. Relationship of BMPR2 mutations to vasoreactivity in pulmonary arterial hyper tension. Circulation 2006;113:2509-15
DOI
ScienceOn
|
12 |
Tueller C, Stricker H, Soccal P, Tamm M, Aubert JD, Maggiorini M, et al. Epidemiology of pulmonary hypertension:new data from the Swiss registry. Swiss Med Wkly 2008;138:379-84
PUBMED
|
13 |
Gali N, Rubin LJ, Hoeper M, Jansa P, Al-Hiti H, Meyer G, et al. Treatment of patients with mildly symptomatic pulmonary arterial hypertension with bosentan (EARLY study): a double-blind, randomised controlled trial. Lancet 2008;371:2093-100
DOI
ScienceOn
|
14 |
Sztrymf B, Coulet F, Girerd B, Yaici A, Jais X, Sitbon O, et al. Clinical outcomes of pulmonary arterial hypertension in carriers of BMPR2 mutation. Am J Respir Crit Care Med 2008;177:1377-83
DOI
ScienceOn
|
15 |
Forfia PR, Mathai SC, Fisher MR, Housten-Harris T, Hemnes AR, Champion HC, et al. Hyponatremia predicts right heart failure and poor survival in pulmonary
arterial hypertension. Am J Respir Crit Care Med 2008;177:1364-9
DOI
ScienceOn
|